Healthcare / Medical DevicesNasdaqGS
$4.91
+0.02 (+0.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-117.2M · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$91M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-64.3%
↓Gross Margin
39.1%
↓Debt/Equity
0.80
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
+79.3%
FCF CAGR
—
FCF margin
-39.4%
FCF / Net income
0.58x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $119.5M · net income $-81.7M · FCF $-47.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | $119.5M | $119.5M | $113.7M | $130.4M | $115.4M | $102.6M | $49.9M | $15.1M | $2.0M |
| Net Income | $-81.7M | $-81.7M | $-128.0M | $-172.8M | $-163.0M | $-131.9M | $-121.5M | $-68.3M | $-49.8M |
| EBITDA | $-62.6M | $-62.6M | $-97.9M | $-153.8M | $-153.9M | $-125.4M | $-114.3M | $-68.8M | $-45.5M |
| EPS | -5.37 | -5.37 | -36.90 | -52.20 | -50.70 | -43.35 | -72.75 | — | — |
| Gross Margin | 39.1% | 39.1% | 33.9% | 22.2% | 15.5% | 7.4% | -26.1% | -118.1% | -304.7% |
| Operating Margin | -55.8% | -55.8% | -99.7% | -130.2% | -139.6% | -127.2% | -235.2% | -466.3% | -2320.0% |
| Net Margin | -68.3% | -68.3% | -112.6% | -132.5% | -141.2% | -128.6% | -243.3% | -453.0% | -2480.3% |
| Balance Sheet | |||||||||
| Debt/Equity | 0.80 | 0.80 | 7.53 | 1.11 | 0.42 | 0.08 | 0.09 | -0.06 | — |
| Current Ratio | 6.29 | 6.29 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-47.1M | $-47.1M | $-117.2M | $-134.8M | $-154.1M | $-133.4M | $-108.1M | $-73.6M | $-48.2M |
| Returns | |||||||||
| ROE | -64.3% | -64.3% | -477.2% | -140.6% | -66.2% | -35.3% | -37.0% | 18.4% | 17.3% |
| Valuation | |||||||||
| P/B | 0.59 | 0.59 | 2.71 | 2.25 | 5.02 | — | — | — | — |
| Growth & Yield | |||||||||
| Revenue Growth | 5.1% | 5.1% | -12.8% | 13.0% | — | 105.5% | 231.2% | 651.3% | — |
| EPS Growth | 85.4% | 85.4% | 29.3% | -3.0% | — | 40.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-72.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-36.90 → -5.37
Residual
-72.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.